Post Reply
5361-5380 of 10899
U'all believe Bengster collect 6000lots...all taken in...previously hve warn agst him since CNA forum ab Ang Tay Kor and his coffee shop kakhis but nobody believe....buy at $0.70 sell at $1.40 if not he will quit this forum...but he is secretly selling
ekekeg ( Date: 12-Nov-2008 16:27) Posted:
Coming tomorrow...Waiting for Bengster to re-enter with 3000 lots. Truly good timing....
XiaoMaGe888 ( Date: 12-Nov-2008 14:52) Posted:
| "Man Man Lai" Coming Soon!!!!!!!!!!!!!!!!!1 |
|
|
|
Closed at $0.265...........Any good news to be announced as you mentioned that coming tomorrow.....What does it mean ?
Coming tomorrow...Waiting for Bengster to re-enter with 3000 lots. Truly good timing....
XiaoMaGe888 ( Date: 12-Nov-2008 14:52) Posted:
"Man Man Lai" Coming Soon!!!!!!!!!!!!!!!!!1
carsem ( Date: 12-Nov-2008 14:46) Posted:
|
|
|
"Man Man Lai" Coming Soon!!!!!!!!!!!!!!!!!1carsem ( Date: 12-Nov-2008 14:46) Posted:
|
unchanged now at $0.265
Needs to cheong down before it chiongs up! Analyst's language goes this way!!
Biosensor started to "cheong" liao.....what happened ?
Neneko, these guys are taking their own sweet time to cover their short selling. They have no believe in BIG so they do it. U shortists, why not try Cosco or Yanzijiang, or Midas hehehe?
Its 1H 08 meeting was on 12 Nov 07. Same day as today.
1H 09 may not be today, thats depend liao.
Above is not a call for anything. CA applies.
AK pick few to try my luck.
XiaoMaGe888 ( Date: 12-Nov-2008 11:22) Posted:
Cheers!!!!!!!!!!!!!!!Hope can CHEONG!!!!!!!!!!
JustForFun ( Date: 12-Nov-2008 11:17) Posted:
For BIG, revenue is more important than profitability as it position itself as a acquisition target. The following 2 paragraphs are extracted from OCBC Research :
Market share vs. profitability. Biosensors' gross margins have and will continue to improve due to 1) sales increase in high margin DES products; 2) better optimisation in balancing direct sales force vs. distributors and; 3)greater efficiencies from its operations. We continue to adhere to our stance that Biosensors will fixate on gaining market share (growing revenue) in the near term vs. cutting costs to attain profitability. This is to gain elevated market presence and to eventually position itself for an acquisition.
Good company, but better target.
While we agree that Biosensors has breakthrough technology, we are mindful that the medtech world continually sees consolidation. As an acquisition target, significant accretion to an acquirer's market share and technology pipeline outweighs profitability concerns. Although details were lacking due to competitive reasons, management updated that its next-gen BioMatrix-Freedom polymer-free DES continues to garner good feedback. Our checks in the US Patent database shows Biosensors' Freedom stent patent was filed on 21 May 2007. Note : The guidance (regarding profitability) given in late 2007 is no longer valid due to the failed JWMS deal.
|
|
|
|
Cheers!!!!!!!!!!!!!!!Hope can CHEONG!!!!!!!!!!JustForFun ( Date: 12-Nov-2008 11:17) Posted:
For BIG, revenue is more important than profitability as it position itself as a acquisition target. The following 2 paragraphs are extracted from OCBC Research :
Market share vs. profitability. Biosensors' gross margins have and will continue to improve due to 1) sales increase in high margin DES products; 2) better optimisation in balancing direct sales force vs. distributors and; 3)greater efficiencies from its operations. We continue to adhere to our stance that Biosensors will fixate on gaining market share (growing revenue) in the near term vs. cutting costs to attain profitability. This is to gain elevated market presence and to eventually position itself for an acquisition.
Good company, but better target.
While we agree that Biosensors has breakthrough technology, we are mindful that the medtech world continually sees consolidation. As an acquisition target, significant accretion to an acquirer's market share and technology pipeline outweighs profitability concerns. Although details were lacking due to competitive reasons, management updated that its next-gen BioMatrix-Freedom polymer-free DES continues to garner good feedback. Our checks in the US Patent database shows Biosensors' Freedom stent patent was filed on 21 May 2007. Note : The guidance (regarding profitability) given in late 2007 is no longer valid due to the failed JWMS deal.
dcang84 ( Date: 12-Nov-2008 09:29) Posted:
|
True revenue is secondary, profits is just about everything. They did give guidance in late 2007. Sorry I dun have them now but I did post it last year. I specifically remember them saying that they would be cashflow positive sometime in 2009. Bengster then gave his version of wat the guidance should have been, much to my chagrin. Well, good things come to those who wait. |
|
|
|
For BIG, revenue is more important than profitability as it position itself as a acquisition target.
The following 2 paragraphs are extracted from OCBC Research :
Market share vs. profitability.
Biosensors' gross margins have and will continue to improve due to 1) sales increase in high margin DES products; 2) better optimisation in balancing direct sales force vs. distributors and; 3)greater efficiencies from its operations. We continue to adhere to our stance that Biosensors will fixate on gaining market share (growing revenue) in the near term vs. cutting costs to attain profitability. This is to gain elevated market presence and to eventually position itself for an acquisition.
Good company, but better target.
While we agree that Biosensors has breakthrough technology, we are mindful that the medtech world continually sees consolidation. As an acquisition target, significant accretion to an acquirer's market share and technology pipeline outweighs profitability concerns. Although details were lacking due to competitive reasons, management updated that its next-gen BioMatrix-Freedom polymer-free DES continues to garner good feedback. Our checks in the US Patent database shows Biosensors' Freedom stent patent was filed on 21 May 2007.
Note : The guidance (regarding profitability) given in late 2007 is no longer valid due to the failed JWMS deal.
dcang84 ( Date: 12-Nov-2008 09:29) Posted:
|
True revenue is secondary, profits is just about everything. They did give guidance in late 2007. Sorry I dun have them now but I did post it last year. I specifically remember them saying that they would be cashflow positive sometime in 2009. Bengster then gave his version of wat the guidance should have been, much to my chagrin. Well, good things come to those who wait.
jackjames ( Date: 11-Nov-2008 21:42) Posted:
|
of course revenue up is a good sign , but you also must generate profits, else, what for good revenue with negative profits?
or at least they should tell us when to turn profit la... no patience liao lei.. arrgghh... |
|
|
|
At least we know that BIG's product is well received looking at its revenue growth. However if u noticed for this quarter (compare to same quarter in 07), gross profit increased by $7m and is exactly offset by increase of operating expenses of $7m. In essense, for every dollar of gross profit, its offset by a dollar of marketing, admin and other cost.
Going forward, BIG should acheive a cost savings of approx $1m per quarter and with enhance branding, revenue should continue to improve while expenses maintained. Also, $2m relates to exchange losses and should not be recurring unless USD keeps appreciating every quarter which is unlikely
Even if they have to raise capital thru a rights issue, I reckon they will do so after they turn the corner. The next two qtrs will be very interesting.
Centaur ( Date: 12-Nov-2008 09:39) Posted:
Might not be able to last that long, BIG got some convertible bonds to repay in 2009 i think. With conversion rate of more than $1, chances are BIG got to come up with some cash to clear these debts, negotiate new debt arrangements or even rights issue
JustForFun ( Date: 11-Nov-2008 23:18) Posted:
the actual cash burn-rate is abt US$10-12m per Q as mentioned in the briefing so US$65m can last for abt 5Qs
|
|
|
|
Look at the brighter side .. when bengster is around ... the price seems like cannot move to the next level .. and with so many fliers flying around suggesting tat this counter may be manipulated ....
So now, with Bengster not around ... who knows things will get better .... although i still miss him super positive outlook report on BIG
Last thing, the CEO now has the latest sales results till Nov which we cant see ... and he is going to MS to do some presentation ..... My personal opinion is tat he should be veri confident and is trying to get some anchor fund manager in for a good time ...... Cos this is not a medical report/result kind of stuff ... it is purely on commercial aspect ....... And furthermore fund are already avoiding counter relating to oil, real estate, manufacturing ....etc But medical is always consider the best haven tp park during crisis... so if the CEO is able to show commitment ... i won't be surprised to see some anchor fund manager to be in soon ....
Or maybe BIG money is running out of money and need investor ..... but chances on this is not high .....
Above juz my personal opinion, not an inducement to trade. Anyway, each to his own .....
Cheers.
Might not be able to last that long, BIG got some convertible bonds to repay in 2009 i think. With conversion rate of more than $1, chances are BIG got to come up with some cash to clear these debts, negotiate new debt arrangements or even rights issue
JustForFun ( Date: 11-Nov-2008 23:18) Posted:
the actual cash burn-rate is abt US$10-12m per Q as mentioned in the briefing so US$65m can last for abt 5Qs
wb1931 ( Date: 11-Nov-2008 22:10) Posted:
| Just run through the financial report for 2Q and noted 15 mil of trade receivables as well as high burn rate for R & D, G & A as well as S & M. While 65 mil seem a lot but can only last max 2Q for overheads. |
|
|
|
True revenue is secondary, profits is just about everything. They did give guidance in late 2007. Sorry I dun have them now but I did post it last year. I specifically remember them saying that they would be cashflow positive sometime in 2009. Bengster then gave his version of wat the guidance should have been, much to my chagrin. Well, good things come to those who wait.
jackjames ( Date: 11-Nov-2008 21:42) Posted:
|
of course revenue up is a good sign , but you also must generate profits, else, what for good revenue with negative profits?
or at least they should tell us when to turn profit la... no patience liao lei.. arrgghh...
dcang84 ( Date: 11-Nov-2008 21:40) Posted:
|
BIG did ok. Why is everyone jumping at their loss? Quite good actually. |
|
|
|
If the loss is not significant, than I would not sell since there are still rays of hope.
Biosensors International Group: Living up to its sales execution promise
Summary: Biosensors International Group (Biosensors) reported 2Q09 topline growth of 95% YoY to US$18m and expectedly continued in its net loss position of US$17.7m. Biosensors’ sales execution did the talking with its BioMatrix DES clocking 399% YoY explosion in sales. Overall, product sales ascended 89% YoY. In a recent key medical conference, Biosensors presented additional data demonstrating strong safety features of its DES. Biosensors’ gross margins have and will continue to improve due to 1) sales increase in high margin DES products; 2) better optimisation in balancing direct sales force vs. distributors and; 3) greater efficiencies from its operations. The group’s desire to focus on growing topline vs. profitability will help to gain market presence and position it for acquisition. We have overhauled our financials with better clarity on projections in China (non consolidated JWMS), cost estimates and product sales acceleration. We are maintaining our medtech discounted model but fair value is now S$0.66 (prev. S$1.03) in view of lower bottomline forecasts. Biosensors trades cheaply at 8.8x next year’s PER. Maintain BUY. (Kelly Chia)
For more information on the above, visit www.ocbcresearch.comfor detailed report.
nothing new expected from this summit, just a conference to promote BIG.
solitary ( Date: 11-Nov-2008 23:24) Posted:
|
A decent set of results, with most of the re-org and cost cutting measures done, the savings will be reflected in the next 2Qs. BIG still expecting losses for the next few Qs but i'm more interested in their DES sales and profit margin (target 65-70%). Interestingly, seem like more & more brokerages are covering BIG.
dcang84 ( Date: 11-Nov-2008 21:40) Posted:
|
BIG did ok. Why is everyone jumping at their loss? Quite good actually.
yipyip ( Date: 11-Nov-2008 18:49) Posted:
|
|
|
